The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.本發明涉及取代的稠合雜環化合物。所述取代的稠合雜環化合物為GPR119調節劑且可用於預防和/或治療糖尿病、肥胖、血脂障礙及相關障礙。本發明還涉及作為藥物中活性成分的取代的稠合雜環化合物的用途,以及包含它們的藥物組合物。